Braidwell’s Third Harmonic Bio THRD Stock Holding History

Braidwell’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,316,018	Closed	-$14.4M	–	81
2023 Q4	$14.4M	Sell	1,316,018 -337,973	-20%	-$2.68M	0.53%	51
2023 Q3	$10.6M	Buy	+1,653,991	New	+$10.1M	0.33%	74

Other funds holding THRD

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell's THRD Position: Q1 2024 in Review

Braidwell sold out of Third Harmonic Bio (THRD) in Q1 2024, closing a stake of 1,316,018 shares — an estimated $14.4M sold.

Braidwell first reported a position in THRD in Q3 2023 and held it in 2 quarters. The position peaked at $14.4M in Q4 2023. 71 funds tracked by Wall St. Rank hold THRD as of Q1 2024.

Braidwell reported no remaining Third Harmonic Bio position as of Q1 2024 after selling out during the quarter.
Braidwell sold 1,316,018 Third Harmonic Bio shares in Q1 2024, an estimated $14.4M.
Braidwell first reported a position in Third Harmonic Bio in Q3 2023 and held it in 2 quarters.
Braidwell's Third Harmonic Bio position peaked at $14.4M in Q4 2023.
71 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2024.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.